178 related articles for article (PubMed ID: 31398516)
1. Photodynamic therapy in a patient with facial angiofibromas due to tuberous sclerosis complex.
Shi M; He S; Chen P; Li Q; Zhu M; Guo J; Jiang L; Wang Q; Peng X; Li S; Li C; Zeng K
Photodiagnosis Photodyn Ther; 2019 Dec; 28():183-185. PubMed ID: 31398516
[TBL] [Abstract][Full Text] [Related]
2. The combination of photodynamic therapy and ultrapulse carbon dioxide laser for facial angiofibromas in tuberous sclerosis complex: A case report.
Wang B; Yao Y; Huang X; Zhang L; Peng D; Zhang G
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102725. PubMed ID: 35041984
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
4. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser.
Weinberger CH; Endrizzi B; Hook KP; Lee PK
Dermatol Surg; 2009 Nov; 35(11):1849-51. PubMed ID: 19682000
[No Abstract] [Full Text] [Related]
5. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
6. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
[TBL] [Abstract][Full Text] [Related]
8. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
11. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
13. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
14. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
15. Unilateral facial angiofibromas--a segmental form of tuberous sclerosis.
McGrae JD; Hashimoto K
Br J Dermatol; 1996 Apr; 134(4):727-30. PubMed ID: 8733380
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
17. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
18. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S
Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350
[No Abstract] [Full Text] [Related]
[Next] [New Search]